Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agios Pharmaceuticals, Inc. - Common Stock (NQ:AGIO)

26.50 -0.57 (-2.09%)
Streaming Delayed Price Updated: 11:17 AM EDT, Apr 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Agios Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Top movers analysis one hour before the close of the markets on 2026-04-20: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
Here's Why Agios Pharmaceuticals Crashed 23% Today ↗
The market is concerned about the diminished market potential for Agios' mitapavit following today's newsflow. 
Via The Motley Fool
What's going on in today's session ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
Agios Pharmaceuticals Inc (NASDAQ:AGIO) Reports Q4 2025 Revenue Beat and Narrower Loss ↗
Via Chartmill
Agios Pharmaceuticals Stock Suffers Record Wipeout As Wall Street Warns Of 'Uncertain' Regulatory Path For Sickle Cell Drug ↗
Via Stocktwits
News headline image
Why Is Agios Pharmaceuticals Stock Surging Tuesday Afternoon? ↗
.Agios Pharmaceuticals Inc (NASDAQ: AGIO) shares are trading sharply higher Tuesday afternoon after the company said it will pursue U.S. accelerated approval for mitapivat in sickle cell disease. 
Via Benzinga
News headline image
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today ↗
The young drugmaker's sickle cell treatment is receiving special consideration from the United States' top drug regulator. 
Via The Motley Fool
News headline image
Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything ↗
Focused on therapies for rare blood disorders, this biotech saw a notable insider sale amid ongoing clinical development efforts. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗
Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs. 
Via The Motley Fool
News headline image
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗
Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Agios (AGIO) Q4 2025 Earnings Call Transcript ↗
Agios (AGIO) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Retail’s Christmas Eve Watchlist: Omeros, Nike, Citi, Dynavax And Agios Spark Most Market Chatter ↗
The stocks were tracked during the shortened Christmas Eve session across healthcare, consumer, and banking. 
Via Stocktwits
Topics ETFs Economy Stocks
News headline image
Here's Why Shares in Agios Pharmaceuticals Popped Today ↗
The company received FDA approval for its leading drug, and investors were pleased with the update from management. 
Via The Motley Fool
News headline image
Which stocks are gapping on Wednesday? ↗
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy
On December 23, 2025, the biotechnology landscape shifted for thousands of patients living with chronic anemia. The U.S. Food and Drug Administration (FDA) granted approval to AQVESME (mitapivat),... 
Via PredictStreet
Topics Economy
News headline image
Why Did AGIO Stock Surge 14% Today? ↗
Agios Pharmaceuticals announced that the FDA approved its oral therapy for anemia in adults with alpha- or beta-thalassemia. 
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Head Into Christmas Eve With Caution: Why ASTS, DVAX, ABVX, PATH, GOOGL Are On Traders' Radar Today ↗
Markets are moving from a record-setting close into a thin, holiday-shortened Christmas Eve session. 
Via Stocktwits
Topics ETFs Stocks
News headline image
This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
 
Via Benzinga
News headline image
This Bellring Brands Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
Nvidia To Rally Around 72%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Agios Pharmaceuticals Plunges Over 50% as Sickle Cell Drug Delivers Mixed Phase 3 Results
Boston, MA – November 19, 2025 – Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) experienced a dramatic and immediate market backlash, with its stock plummeting over 51.00% following the announcement of... 
Via MarketMinute
News headline image
Which stocks are moving on Wednesday? ↗
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Why Shares in Agios Pharmaceuticals Got Crushed Today ↗
The company's pivotal Phase 3 trial hit one primary endpoint but missed another. 
Via The Motley Fool
News headline image
Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results ↗
 
Via Benzinga
News headline image
Why Is Agios Pharmaceuticals Stock Sinking Today? ↗
Agios stock drops as mitapivat's Phase 3 trial shows strong hemoglobin gains but limited impact on sickle cell pain crises, prompting mixed investor reaction. 
Via Benzinga
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
AGIO Stock Cracks After Sickle-Cell Disease Drug Delivers Mixed Results In Late-Stage Trial ↗
While Mitapivat also showed a reduction in the primary endpoint of annualized rate of sickle cell pain crises (SCPCs) compared to placebo, this trend did not achieve statistical significance, Agios... 
Via Stocktwits
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.